CDK16

Across TCGA pan-cancer cohorts, CDK16 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated CDK16 data layer compared with 2 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CDK16 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CDK16 expression acts as an unfavorable survival marker, although some lineages such as OV and SCLC show a favorable association.

LIHC, ACC, and KICH are the cancer types where CDK16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.593	0.777	<.001	89	view →
ACC	DFS	Median	All	0.257	0.657	<.001	88	view →
KICH	OS	Median	All	0.841	1.000	.001	73	view →
KIRC	DFS	Quartile	II,III,IV	0.682	0.850	.006	65	view →
ESCA	DFS	Quartile	II,III,IV	0.361	0.670	<.001	46	view →
MESO	OS	Quartile	III,IV	0.424	0.729	.001	45	view →
UVM	DFS	Tertile	II,III,IV	0.359	0.711	.001	38	view →
BRCA	OS	Median	All	0.949	0.975	.002	36	view →
COAD	DFS	Tertile	All	0.725	0.838	.004	35	view →
LUAD	DFS	Quartile	All	0.580	0.737	.002	33	view →
SARC	OS	Median	All	0.396	0.613	<.001	31	view →
PAAD	OS	Tertile	All	0.415	0.715	.003	30	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

CDK16–LIHC (OS)

Open the LIHC breakdown →